Vigorous Sports Participation and Plasma Lipids in Lean Adolescents: ABCD Growth Study.

Int J Sports MedJun 11, 2026 (epub)
Clinical ResearchPediatricsEndocrinology

Ana Elisa von Ah Morano, Jeff S Coombes, Romulo Fernandes

✦ AI-curated · Sources linked

In 30 seconds

This clinical trial examined the impact of vigorous sports participation on plasma lipid levels in lean adolescents aged 11-17 years. Over 12 months, the study found that engaged boys had a change in the atherogenic index of plasma of -0.021, while girls showed a change of -0.062, indicating improved lipid profiles associated with sports participation.

Key findings

  • Boys engaged in sports had an atherogenic index change of -0.021 compared to 0.117 for those not engaged.
  • Girls engaged in sports had an atherogenic index change of -0.062 compared to 0.098 for those not engaged.
  • Changes in lean soft tissue were a significant determinant of lipid changes in boys (r = -0.415, p = 0.050).
  • Vigorous physical activity was a significant determinant of lipid changes in girls (r = -0.291, p = 0.012).

Why it matters

Understanding the relationship between sports participation and lipid profiles in adolescents can inform strategies to promote physical activity, potentially reducing future cardiovascular risks in this population.

Source

PubMed · PMID 42276112

Published in Int J Sports Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.